DDInter1089 DDInter927
Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability and extensive biotransformation. Ritonavir is a potent inhibitor of the enzymes responsible for lopinavir metabolism, and its co-administration "boosts" lopinavir exposure and improves antiviral activity. Like many other protease inhibitors (e.g. [saquinavir], [nelfinavir]), lopinavir is a peptidomimetic molecule - it contains a hydroxyethylene scaffold that mimics the peptide linkage typically targeted by the HIV-1 protease enzyme but which itself cannot be cleaved, thus preventing the activity of the
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lopinavir {u} (Compound) resembles {v} (Compound) Saquinavir
Lopinavir {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Lopinavir {u} (Compound) binds {v} (Gene) ABCB1
Lopinavir {u} (Compound) upregulates {v} (Gene) EDEM1
Lopinavir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Lopinavir {u} (Compound) downregulates {v} (Gene) GJA1
Lopinavir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Lopinavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Lopinavir {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Lopinavir (Compound) resembles Saquinavir (Compound)
Lopinavir (Compound) treats acquired immunodeficiency syndrome (Disease)
Lopinavir (Compound) binds ABCB1 (Gene)
Lopinavir (Compound) upregulates EDEM1 (Gene)
Lopinavir (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Lopinavir (Compound) downregulates GJA1 (Gene)
Lopinavir may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin
Lopinavir may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Lopinavir may lead to a major life threatening interaction when taken with Fingolimod